anti-cd47

Anti-CD47 Antibody (B6.H12) is a chimeric mouse IgG1 κ antibody that specifically targets human CD47. The recommended isotype control for Anti-CD47 Antibody (B6.H12) is Mouse IgG1 kappa, Isotype Control.

Anti-CD47 (A4) antibody is a kind of antibody that can be used for Blocking, functional assays, FC and other related research.

Anti-CD47 (h4C1) antibody is a kind of antibody that can be used for activity assays, functional studies, binding affinity analysis, and other applications, serving as an essential tool in biological research.

Anti-CD47 Antibody (VxP037) is a kind of antibody that can be used for blocking and other related research.

Magrolimab (Hu5F9-G4) is a humanized anti-CD47 IgG4 monoclonal antibody that exhibits antitumor activity by blocking CD47 and binding primarily to the N-terminal pyroglutamate of CD47. It can be used in combination with other compounds for the treatment of recurrent myeloma.

CC-90002 is a humanized monoclonal antibody targeting CD47 that inhibits CD47-SIRPα interactions, suitable for studying hematologic malignancies such as leukemia.

Ligufalimab (AK 117) is a humanized IgG4 monoclonal antibody that targets CD47 without inducing red blood cell hemagglutination. Ligufalimab enhances phagocytosis and demonstrates significant antitumor activity. Due to its safety and activity profile, Ligufalimab is considered a promising therapeutic antibody candidate in oncology research.

Lemzoparlimab (TJ011133) is a differentiated anti-CD47 humanized antibody with anti-tumor activity, used in the study of myeloid leukemia.

Anzurstobart, a fully human monoclonal anti-SIRPα antibody, is characterized by high-affinity binding and inhibition of the CD47-SIRPα interaction, which is known to suppress macrophage activity. Anzurstobart enhances macrophage-mediated phagocytosis of diffuse large B-cell lymphoma (DLBCL) cell lines in co-culture with Rituximab, and it shows considerable promise in both solid and hematologic malignancy research, positioning it as a potential candidate for immuno-oncology applications.

AO-176 is a humanized anti-CD47 IgG2 monoclonal antibody. It induces tumor phagocytosis by blocking the interaction between CD47 and SIRPα. AO-176 preferentially binds to tumor cells over normal cells and directly kills tumor cells through a cell-autonomous mechanism, rather than via antibody-dependent cellular cytotoxicity (ADCC). In tumor xenograft models, AO-176 demonstrates dose-dependent antitumor activity. This compound is applicable in cancer research, such as studies involving lymphoma.

Anti-Human CD47 Antibody (B6H12) is a monoclonal antibody targeting human CD47 and can be used in cancer immunotherapy research.

Anti-Mouse CD47/IAP Antibody (MIAP301) is a monoclonal antibody inhibitor targeting mouse CD47/IAP. It enhances macrophage phagocytosis and immune cell infiltration, restores myeloid cell phagocytic function, and alleviates B-cell suppression. It can be used in research on cancer, inflammation, and infectious diseases.

Anti-Mouse/Rat/Human CD47/IAP Antibody (MIAP410) is an IgG1 monoclonal antibody specifically directed against mouse, rat, and human CD47/IAP. It effectively blocks CD47-mediated signaling to enhance macrophage phagocytic activity, promote immune cell infiltration into tissues, potentially interfere with wound healing processes, and support experimental investigations in oncology and inflammatory disease models, including but not limited to breast cancer research and studies of intestinal mucosal repair mechanisms.

STI-6643 is a fully human IgG4 antibody that targets and binds to CD47. It exhibits potent anti-tumor activity with negligible toxicity towards red blood cells and lymphocytes. The isotype control for STI-6643 can be referenced as HumanIgG4(S228P) kappa, Isotype Control.